Skyrizi trumps Cosentyx over a year in psoriasis

15 January 2020

US drugmaker AbbVie’s (NYSE: ABBV) Skyrizi (risankizumab) has met both primary and all ranked secondary endpoints, including superiority at week 52, in a comparison with Cosentyx (secukinumab) in moderate to severe plaque psoriasis.

Skyrizi showed significantly higher rates of skin clearance compared to the Novartis (NOVN: VX) drug, meeting the primary endpoint of superiority with at least a 90% improvement from baseline in the psoriasis area and severity index (PASI 90) at week 52.

"Head-to-head data like these are crucial to help patients and their doctors make informed treatment decisions"Of those who received Skyrizi, 87% achieved PASI 90 compared to 57% of Cosentyx-treated patients, after a year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK